1. Introduction {#sec1}
===============

Hematopoietic stem cell transplantation (HSCT) is a potentially curative therapy for a variety of malignant and nonmalignant hematological disorders \[[@B1], [@B2]\]. Since the first transplant, performed in 1939 \[[@B3]\], this procedure has evolved with advances in conditioning, HLA compatibility techniques, supportive care, management of complications, and expanding stem cells sources \[[@B2], [@B4]--[@B9]\]. As a result, indications for transplant and the pool of eligible patients have increased, notably allowing inclusion of elderly recipients \[[@B10]\] and increasing the annual number of unrelated HSCT, now exceeding 10.000 worldwide \[[@B11]\].

Allogeneic HSCT remains, however, associated with a significant risk of morbidity and mortality. This procedure can induce damage of various organs and tissues, from subclinical changes to life-threatening conditions \[[@B4], [@B12], [@B13]\], justifying the development of scores for the assessment of HSCT risk in a particular patient. On the other hand, nontransplant treatment strategies \[[@B14]--[@B17]\] have improved in recent years, particularly for chronic myeloid leukemia (CML).

In 1998, the EBMT (European Group for Blood and Marrow Transplantation) validated a simple risk score for patients submitted to allogeneic HSCT for CML based on five risk factors: age of recipient, disease stage, time interval from diagnosis to transplantation, donor type, and donor-recipient gender combination \[[@B18]\]. It is interesting to note that De Souza et al. \[[@B19]\] validated the EBMT score in a population of 1084 Brazilian CML patients. Later, in a retrospective analysis, the EBMT extended the score utility to a broad range of acquired hematological disorders, improving transplant risk assessment in general \[[@B17]\]. The latter was later tested and modified for different diseases and clinical situations \[[@B20]--[@B22]\].

The aim of this study was to validate the applicability of the EBMT risk score for allogeneic HSCT on South Brazilian patients with acquired hematological disorders from a single center at Hospital de Clínicas de Porto Alegre, Brazil.

2. Patients and Methods {#sec2}
=======================

2.1. Study Design and Database {#sec2.1}
------------------------------

A retrospective observational study was performed based on the review of patients\' charts and database at the Hematology and Bone Marrow Transplantation Department of Hospital de Clínicas de Porto Alegre (HCPA), Brazil. This data holds information on 293 patients submitted to allogeneic HSCT performed between 1994 and 2010. Except for syngeneic donor transplants and HSCT performed for nonmalignant diseases other than aplastic anemia, all HLA-identical sibling and unrelated donor transplants were included.

2.2. Definitions of Risk Score and Endpoints {#sec2.2}
--------------------------------------------

This analysis utilizes the original EBMT (European Group for Blood and Marrow Transplantation) risk score as reported and later adapted by Gratwohl et al. \[[@B17], [@B18]\], with five pretransplant risk factors: age of the patient, disease stage, time from diagnosis to transplant, donor type, and donor-recipient gender combination. The total risk score for an individual patient is the sum of points given to each variable, which can range from 0 to 7 points. Risk factors were distributed as age of recipient (0 for \<20 years, 1 for 20--40 years, and 2 for \>40 years); donor type (0 for HLA-identical sibling donor and 1 for unrelated donor); gender match (0 for all others and 1 for male recipient/female donor); time from diagnosis to transplantation (0 for \<12 months and 1 for \>12 months). Disease stage was categorized as early stage (0 point) including acute leukemia transplanted in first complete remission (CR), myelodysplastic syndrome (MDS) transplanted either untreated or in first CR, CML in first chronic phase, and lymphoproliferative disorders and multiple myeloma (MM) in first CR. Intermediate stage (1 point) includes acute leukemia in second CR, CML in all other stages except chronic phase and blast crisis, MDS in second CR or in partial remission, and lymphoproliferative disorders and MM in second CR, partial remission, or stable disease. Late stage disease (2 points) includes acute leukemia in all other disease stages, CML in blast crisis, MDS, lymphoproliferative disorders, and MM in all other stages than those previously defined. Disease stage in patients with severe aplastic anemia (SAA) was always considered as early stage (0 point). Donor and recipient CMV serologic status was also analyzed in our population.

Overall survival (OS), nonrelapse mortality (NRM), and relapse rate (RR) were the three endpoints analyzed in this study. Overall survival was defined as the probability of survival from transplant to death from any cause, with surviving patients censored at the last followup. NRM was defined as the probability of dying due to any cause other than disease recurrence and RR as the probability of disease recurrence \[[@B15]\].

2.3. Statistical Analysis {#sec2.3}
-------------------------

The calculations were done by SPSS v.18.0, and each endpoint was analyzed separately. Quantitative variables are described by median and range and categorical variables by frequencies and percentages. 95% confidence intervals were presented. Overall survival was estimated from the time of transplant using Kaplan-Meier curve method. NRM and relapse were calculated using cumulative incidence estimates. For each endpoint and each studied disease, a Cox regression model with a proportional hazards analysis was applied using the five risk factors. The predictive power of the EBMT risk score was calculated for total population and for each disease by computing the receiver operating characteristics area under the curve (ROC AUC) for each endpoint.

2.4. Ethical Aspects {#sec2.4}
--------------------

This study was approved by the Ethics Committee of HCPA under number 09-607 and the data was analyzed anonymously according to Declaration of Helsinki for human studies.

3. Results {#sec3}
==========

3.1. Patient Population {#sec3.1}
-----------------------

In total, 293 patients submitted to allogeneic HSCT were included. Of those, 16 patients were not eligible: eleven patients had nonmalignant disorders other than SAA and in 5 the information was not available.

From the 278 evaluable patients 156 were male (56%), with a median age of 32 years, ranging from 1 to 57 years. Fifty-nine patients had acute myeloid leukemia (AML), 48 ALL, 16 MDS, 76 CML, 27 lymphoproliferative disorders, 1 MM, and 51 SAA. Most procedures (238) were performed with HLA-identical sibling and 40 with HLA-matched and mismatched unrelated donors. Bone marrow was the stem-cell source in 220, peripheral blood in 52, and cord blood in 6 patients. Of the entire group of patients, 241 were submitted to myeloablative and 37 to reduced intensity conditioning regimens. Most transplants were performed at early disease stage (175 patients, 62.9%) and with more than 12 months from diagnosis. The sums of risk score points were 2 and 3 for the majority of patients (138 patients, 49.6%). No recipient had scored 7. The population characteristics are summarized in [Table 1](#tab1){ref-type="table"}.

3.2. Overall Survival {#sec3.2}
---------------------

The cumulative OS for the entire population was 48.7% at five years (95% confidence interval, 42.5%--54.9%) and 43.9% (95% CI, 37.1%--50.7%) at ten years. Median follow-up for surviving patients was 6.39 years, ranging from 58 days to 15 years ([Figure 1](#fig1){ref-type="fig"}).

There was a significant relation between the sum of risk score points and survival. Overall survival in five years decreases significantly from 81.8% on risk score 0 to 0% on score 6 (*P* \< 0.001). Risk score 0 had a statistical difference when compared with scores 3, 4, 5, and 6 (*P* = 0.034; 0.003; 0.003; and \<0.001, resp.). A significant difference was also observed between score 1 when compared to scores 4, 5, and 6, and scores 3 and 4 to score 6 (*P* = 0.010; 0.018; and 0.005, resp.) ([Figure 2](#fig2){ref-type="fig"}).

Some risk factors had a significant impact on survival for different diseases. For our total population, disease stage, time interval between disease diagnosis and HSCT, and donor type were the risk factors with significant impact on overall survival. Age, disease stage, and gender combination had significant impact only for AML, and donor type was statistically significant for AML and CML. The predictive power of the score for all diseases, analyzed by ROC AUC, was 0.667, ranging from 0.590 for SAA to 0.802 for AML. Proportional hazards were not performed to MDS, MM, and lymphoproliferative disorders because of the small number of patients. Hazard ratio on overall survival for all patients and for each disease is shown in [Table 2](#tab2){ref-type="table"}.

3.3. Nonrelapse Mortality {#sec3.3}
-------------------------

Cumulative nonrelapse mortality was 40.7% at five years (95% CI, 34.5%--46.9%) and 44.6% (95% CI, 37.6%--51.6%) at ten years ([Figure 3](#fig3){ref-type="fig"}). The NRM increased from 13.6% for risk score 0 to 80% for score 6 (*P* = 0.001). Risk score 0 was statistically different to scores 2, 3, 5, and 6 (*P* = 0.044; 0.034; 0.004; and 0.001, resp.), as score 1 to score 6 (*P* = 0.029) ([Figure 4](#fig4){ref-type="fig"}). Evaluating risk factors for NRM, advance disease stage (HR 3.8 (1.3--11.0)), and gender combination (HR 2.6 (1.1--6.4)) had significant difference for AML and donor type (HR 4.1 (1.7--10.2)) for CML. The predictive power for all diseases was 0.59, ranging from 0.55 for ALL to 0.77 for AML.

3.4. Relapse Rate {#sec3.4}
-----------------

The RR of the entire population was 30.7% at five years (95% CI, 23.3%--38.1%) and 32.4% at ten years (95% CI, 24.4%--40.4%). For relapse, advanced disease stage had significant impact for ALL (HR 9.6 (2.6--36.0)), AML (HR 7.3 (2.2--24.0)), and CML (HR 5.1 (1.1--24.2)) and gender combination for ALL (HR 3.5 (1.2--10.1)). The predictive power for all diseases was 0.630, ranging from 0.47 for CML to 0.76 for ALL. Deaths from relapse were 22.1% at five years (95% CI, 15.5%--28.7%) and 28.5% at ten years (95% CI, 20.5%--36.5%) ([Figure 5](#fig5){ref-type="fig"}). The relation between relapse rate and prognostic scoring system was not statistically significant.

3.5. CMV Serologic Status {#sec3.5}
-------------------------

CMV serologic status was positive in 238 (86.5%) patients and there was no significant difference on overall survival between seropositive and seronegative recipients or between donor/recipient combinations of CMV serology ([Table 1](#tab1){ref-type="table"}).

4. Discussion {#sec4}
=============

Hematopoietic stem cell transplantation is a treatment modality able to cure many hematological disorders, but morbimortality rates remain high \[[@B18], [@B23], [@B24]\]. Efforts have been made trying to integrate pretransplant clinical variables into a single score in order to predict outcomes in HSCT recipients \[[@B25]--[@B27]\]. The aim of our study was to validate the 2009 EBMT risk score \[[@B17]\] in a single Brazilian center for all acquired hematological disorders.

Of the 278 patients, with a median age of 32 years, the majority (86.5%) had a positive serologic status for CMV, precluding statistical analysis, and were submitted to a matched-related, myeloablative allogeneic HSCT for an early stage disease. The median time interval from diagnosis to transplant was over 12 months, and the stem cell source more frequently used was bone marrow. OS, NRM, and death from relapse at five years were 48.7%, 40.7%, and 22.1%, respectively (Figures [1](#fig1){ref-type="fig"}, [3](#fig3){ref-type="fig"}, and [5](#fig5){ref-type="fig"}). Although in a much smaller and different ethnic population of patients, precluding a strait forward comparison, our data differs from Gratwohl et al. \[[@B17]\] in time interval to transplant since the majority of the European patients were transplanted less than 12 months after diagnosis. The extended time to transplant observed in our population was probably due to a delay in referral to HSCT as previously shown in a Brazilian population \[[@B19]\].

Overall, the EBMT risk score has proved to be a reasonable tool to predict OS at our center. As shown by the EBMT group, patients with lower risk scores had a better OS after HSCT, and advanced disease stage, longer time interval from diagnosis to transplant, and unrelated donor were powerful predictors of worse survival in our population.

As for the stronger predictive value for AML (AUC: 0.802), observed in our group of patients, we could argue that, besides size sample, ours was a positively selected group of AML patients since the majority of patients were transplanted in first remission in a longer time interval to transplant. It is reasonable to speculate that for such long disease-free survival before transplant, patients were selected by attending a better remission with corresponding better prognosis \[[@B28]\]. As can be noted ([Table 2](#tab2){ref-type="table"}), time interval to transplant was not significant for this as well as for any group of our patients. Recently, a modified EBMT risk score was proposed and validated to ALL and AML patients \[[@B20], [@B21]\], omitting time from diagnosis to transplantation since this parameter could be more susceptible to multiple sources of bias \[[@B1], [@B28]\], including a strong correlation with disease stage \[[@B21]\]. In addition, it is of note that most ALL patients in first CR were at high risk (Ph+ ALL and other cytogenetic unfavorable leukemias) (data not shown), whereas our CML patients were transplanted after over 12 months in first chronic phase which has been shown, as itself, to be predictive of a worse outcome \[[@B18]\]. These findings could explain why the predicted risk value was weaker, although in accordance to the EBMT findings \[[@B17]\], compared to our group of probably selected AML patients.

Finally, NRM and RR were also associated with risk scores categories but with a poorer predictive power than overall survival. Confirming the international literature \[[@B29]\], advanced disease stage was an independent risk factor associated with increased relapse rate in all malignancies (AML, ALL, and CML) evaluated in our study. Lymphoproliferative disorders, MDS, and MM had no sufficient number of patients to allow a reliable analysis. Although not considered as a risk factor at the EBMT score system, CMV serologic status, recognized as a negative risk factor for NRM and OS after HSCT \[[@B30]\], could not be evaluated in our sample of patients due to the very high incidence observed of CMV positivity.

In conclusion, here we demonstrated that the EBMT score can be utilized as a tool for clinical decision making for malignant and nonmalignant hematological disorders in a single center in Brazil. It should be noted that been retrospective and studying a consecutive cohort of patients from 1994 to 2010, its limitation is to have included mostly young and good risk patients. It will be necessary to test this predictive model prospectively since the present day population has a larger proportion of patients with more resistant diseases partially related to the use of newer agents or more extensive pretreatment with conventional drug combinations.
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###### 

Patients distribution.

  Category        AML          ALL          CML          MDS          MM         LD           SAA          Total
  --------------- ------------ ------------ ------------ ------------ ---------- ------------ ------------ -------------
  Sex                                                                                                      
  Male            33 (55.9%)   30 (62.5%)   45 (59.2%)   6 (37.5%)    1 (100%)   12 (44.4%)   29 (56.9%)   156 (56.1%)
  Female          26 (44.1%)   18 (37.5%)   31 (40.8%)   10 (62.5%)   0          15 (55.6%)   22 (43.1%)   122 (43.9%)
                                                                                                           
  Source                                                                                                   
  BM              49 (83.1%)   41 (85.4%)   63 (82.9%)   11 (68.8%)   0          7 (25.9%)    49 (96.1%)   220 (79.1%)
  PBSC            10 (16.9%)   3 (6.3%)     13 (17.1%)   4 (25%)      1 (100%)   20 (74.1%)   1 (2%)       52 (18.7%)
  CB              0            4 (8.3%)     0            1 (6.3%)     0          0            1 (2%)       6 (2.2%)
                                                                                                           
  Regimen                                                                                                  
  Myeloablative   58 (98.3%)   48 (100%)    76 (100%)    12 (75%)     0          0            46 (90.2%)   241 (86.7%)
  RIC             1 (1.7%)     0            0            4 (25%)      1 (100%)   27 (100%)    5 (9.8%)     37 (13.3%)
                                                                                                           
  Patient age                                                                                              
  Median          35           15           36.5         35           31         43           20           32
  Range           1--55        1--47        7--57        2--55        31         18--56       5--51        1--57
                                                                                                           
  Age                                                                                                      
  \<20            14 (23.7%)   27 (56.3%)   6 (7.9%)     4 (25%)      0          2 (7.4%)     26 (51%)     79 (28.4%)
  20--40          27 (45.8%)   16 (33.3%)   40 (52.6%)   6 (37.5%)    1 (100%)   10 (37%)     19 (37.3%)   119 (42.8%)
  \>40            18 (30.5%)   5 (10.4%)    30 (39.5%)   6 (37.5%)    0          15 (55.6%)   6 (11.8%)    80 (28.8%)
                                                                                                           
  Disease stage                                                                                            
  Early           28 (47.5%)   18 (37.5%)   60 (78.9%)   16 (100%)    0          2 (7.4%)     51 (100%)    175 (62.9%)
  Intermediate    17 (28.8%)   23 (47.9%)   12 (15.8%)   0            1 (100%)   7 (25.9%)    ---          60 (21.6%)
  Advanced        14 (23.7%)   7 (14.6%)    4 (5.3%)     0            0          18 (66.7%)   ---          43 (15.5%)
                                                                                                           
  Time interval                                                                                            
  \<12 months     24 (40.7%)   13 (27.1%)   13 (17.1%)   5 (31.3%)    0          1 (3.7%)     36 (70.6%)   92 (33.1%)
  \>12 months     35 (59.3%)   35 (72.9%)   63 (82.9%)   11 (68.7%)   1 (100%)   26 (96.3%)   15 (29.45)   186 (66.9%)
                                                                                                           
  HLA                                                                                                      
  HLA IS          50 (84.7%)   33 (68.8%)   69 (90.8%)   14 (87.5%)   1 (100%)   27 (100%)    44 (86.3%)   238 (85.6%)
  Unrelated       9 (15.35)    15 (31.3%)   7 (9.2%)     2 (12.5%)    0          0            7 (13.7%)    40 (14.4%)
                                                                                                           
  Gender com                                                                                               
  Other           42 (71.2%)   34 (70.8%)   58 (76.3%)   16 (100%)    0          21 (77.8%)   38 (74.5%)   209 (75.2%)
  DF/RM           17 (28.8%)   14 (29.2%)   18 (23.7%)   0            1 (100%)   6 (22.2%)    13 (25.5%)   69 (24.8%)
                                                                                                           
  Score                                                                                                    
  0               2 (3.4%)     4 (8.3%)     1 (1.3%)     2 (12.5%)    0          0            13 (25.5%)   22 (7.9%)
  1               10 (16.9%)   6 (12.5%)    7 (9.2%)     4 (25%)      0          0            18 (35.3%)   45 (16.2%)
  2               17 (28.8%)   12 (25%)     20 (26.3%)   3 (18.8%)    0          1 (3.7%)     13 (25.5%)   66 (23.7%)
  3               9 (15.3%)    12 (25%)     35 (46.1%)   7 (15.3%)    0          3 (11.1%)    6 (11.8%)    72 (25.9%)
  4               10 (16.9%)   11 (22.9%)   9 (11.8%)    0            1 (100%)   11 (40.7%)   1 (2.0%)     43 (15.5%)
  5               8 (13.6%)    2 (4.2%)     4 (5.3%)     0            0          11 (40.7%)   0            25 (9.0%)
  6               3 (5.1%)     1 (2.1%)     0            0            0          1 (3.7%)     0            5 (1.8%)
                                                                                                           
  CMV                                                                                                      
  Recipient pos   52 (91.2%)   37 (77.1%)   65 (85.5%)   14 (87.5%)   1 (100%)   23 (88.5%)   46 (90.2%)   238 (86.5%)
  Recipient neg   5 (8.8%)     11 (22.9%)   11 (14.5%)   2 (12.5%)    0          3 (11.5%)    5 (9.8%)     37 (13.5%)

AML: acute myeloid leukemia; ALL: acute lymphoblastic leukemia; CML: chronic myeloid leukemia; MDS: myelodysplastic syndrome; MM: multiple myeloma; LD: lymphoproliferative disorders; SAA: severe aplastic anemia; BM: bone marrow; PBSC: peripheral blood stem cell; CB: cord blood; HLA IS: human leukocyte antigen identical sibling; Gender com: gender combination between donor and recipient; DF/RM: donor female/recipient male; CMV: cytomegalovirus; neg: negative; pos: positive.

###### 

Impact of pretransplant risk factors on overall survival.

  Risk factors         AML               ALL              CML              AA               Total
  -------------------- ----------------- ---------------- ---------------- ---------------- ----------------
  Age class                                                                                 
  \<20                 1                 1                1                1                1
  20--40               3.4 (1.0--11.7)   1.3 (0.6--2.8)   0.9 (0.3--3.0)   1.7 (0.7--4.5)   1.4 (0.9--2.2)
  \>40                 3.8 (1.1--13.7)   1.4 (0.5--3.9)   1.1 (0.3--3.9)   1.1 (0.2--5.3)   1.4 (0.9--2.2)
                                                                                            
  Disease stage                                                                             
  Early                1                 1                1                1                1
  Intermediate         2.1 (0.8--5.4)    1.4 (0.6--3.0)   1.9 (0.9--4.0)   ---              1.5 (1.0--2.2)
  Advanced             5.1 (2.1--12.8)   2.4 (0.9--6.3)   2.1 (0.6--6.8)   ---              2.0 (1.3--3.1)
                                                                                            
  Time interval                                                                             
  \<12 months          1                 1                1                1                1
  \>12 months          1.8 (0.8--3.8)    0.8 (0.4--1.8)   1.7 (0.7--4.3)   1.4 (0.5--3.5)   1.5 (1.1--2.2)
                                                                                            
  Donor type                                                                                
  HLA                  1                 1                1                1                1
  Other                3.0 (1.3--7.1)    1.6 (0.8--3.3)   3.6 (1.5--8.6)   1.7 (0.6--5.2)   2.4 (1.6--3.6)
                                                                                            
  Gender combination                                                                        
  Other                1                 1                1                1                1
  DF/RM                2.4 (1.2--5.1)    1.9 (0.9--4.0)   0.7 (0.3--1.4)   0.8 (0.3--2.3)   1.1 (0.8--1.7)
                                                                                            
  ROC curve                                                                                 
  AUC                  0.802             0.743            0.631            0.590            0.667

AML: acute myeloid leukemia; ALL: acute lymphoblastic leukemia; CML: chronic myeloid leukemia; HLA IS: human leukocyte antigen identical sibling; DF/RM: donor female/recipient male; ROC AUC: receiver operating characteristics area under the curve.
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